SCHEMBL19220845

SCHEMBL19220845

CNC(=O)c1c[nH]c2c([N+](=O)[O-])cccc2c1=O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNA2 P51530 1/20 0.72
CASP6 P55212 1/20 0.72
CTDSP1 Q9GZU7 1/20 0.72
GUSB P08236 5/20 0.54
SLC6A2 P23975 1/20 0.46
SLC6A4 P31645 1/20 0.46
SLC6A3 Q01959 1/20 0.46
RAB9A P51151 3/20 0.45
POLB P06746 2/20 0.45
ALDH1A1 P00352 5/20 0.43
HPGD P15428 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
KDM4E B2RXH2 1/20 0.43
NPC1 O15118 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6537720 0.85 DNA2 (0.78) DNA2CASP6CTDSP1GUSBALDH1A1
SCHEMBL19220852 0.84 DNA2 (0.71) DNA2CASP6CTDSP1GUSBRAB9A
SCHEMBL4334739 0.84 DNA2 (1.00) DNA2CASP6CTDSP1GUSBALDH1A1
SCHEMBL19220847 0.83 DNA2 (0.62) DNA2CASP6CTDSP1GUSBRAB9A
SCHEMBL19226218 0.81 DNA2 (0.60) DNA2CASP6CTDSP1GUSBRAB9A
SCHEMBL20153429 0.80 DNA2 (0.62) DNA2CASP6CTDSP1GUSBRAB9A
SCHEMBL19220846 0.79 DNA2 (0.57) DNA2CASP6CTDSP1GUSBRAB9A
SCHEMBL4739348 0.79 CLEC4M (0.71) DNA2CASP6CTDSP1GUSBPOLB
SCHEMBL3066032 0.78 DNA2 (0.66) DNA2CASP6CTDSP1GUSBALDH1A1
SCHEMBL21993978 0.78 DNA2 (0.58) DNA2CASP6CTDSP1GUSBPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11780815-B2 DNA2 inhibitors for cancer treatment CITY OF HOPE (US) 2023-10-10 US disclosed
US-20180134664-A1 DNA2 INHIBITORS FOR CANCER TREATMENT CITY OF HOPE 2018-05-17 US disclosed
US-9932310-B2 DNA2 inhibitors for cancer treatment CITY OF HOPE (US) 2018-04-03 US disclosed
US-20170226063-A1 DNA2 INHIBITORS FOR CANCER TREATMENT CITY OF HOPE 2017-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134664-A1 DNA2 INHIBITORS FOR CANCER TREATMENT DNA2, TOP2A, TOP2B DNA2 1/4885CASP6 2412/4885CTDSP1 20/4885
US-20170226063-A1 DNA2 INHIBITORS FOR CANCER TREATMENT DNA2, TOP2A, TOP2B DNA2 1/4885CASP6 2412/4885CTDSP1 20/4885
US-11780815-B2 DNA2 inhibitors for cancer treatment DNA2, TOP2A, TOP2B DNA2 1/4885CASP6 2412/4885CTDSP1 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.